{"id":{"repo_id":"athens","oai_identifier":"oai:lib.uoa.gr:uoadl:2876520"},"canonical_url":"https://search.ndltd.org/etd/athens/oai:lib.uoa.gr:uoadl:2876520","repository":{"repo_id":"athens","name":"National and Kapodistrian University of Athens","base_url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh"},"display":{"title":"Χρήση τρανεξαμικού οξέoς στη χειρουργική αντιμετώπιση των καταγμάτων ισχίου- ανασκόπηση","abstract":"Τα κατάγματα ισχίου είναι από τις ορθοπεδικές επεμβάσεις που συνοδεύονται με τη μεγαλύτερη διεγχειρητική και μετεγχειρητική απώλεια αίματος (1). Η μετάγγιση συμπυκνωμένων ερυθρών αιμοσφαιρίων είναι ο συνήθης τρόπος αντιμετώπισης της απώλειας αίματος κατά τη διάρκεια των επεμβάσεων αυτών. Απώλεια αίματος της τάξης των 1000 ml συνήθως οδηγεί σε μετεγχειρητική αναιμία και απαιτεί μετάγγιση, μια πράξη που ελοχεύει τον κίνδυνο μετάδοσης ιογενών νοσημάτων, αλλεργικές και ανοσοτροποποιητικές αντιδράσεις (2). Συχνά υπάρχει το πρόβλημα των διαθέσιμων φιαλών αίματος οδηγώντας την ιατρική κοινότητα να ερευνήσει τρόπους ή παρεμβάσεις, που έχουν ως στόχο τη μείωση της ανάγκης των μεταγγίσεων (2). Η Μετάγγιση αίματος μετά από ορθοπεδικές επεμβάσεις ανήκει στο 10% όλων των μονάδων αίματος που χορηγούνται από την αιμοδοσία του Εθνικού Συστήματος Υγείας (3). Ο στόχος της μετάγγισης των ερυθρών αιμοσφαιρίων είναι να αυξήσει τη συγκέντρωση της αιμοσφαιρίνης και ως εκ τούτου τη μεταφορά του οξυγόνου στους ιστούς. Παρόλα ταύτα, δεν υπάρχουν κατευθυντήριες οδηγίες όσον αφορά στην μετάγγιση. Επιπρόσθετα, τα δεδομένα της τελευταίας δεκαετίας προτείνουν ως ασφαλές όριο μετάγγισης, τιμή αιμοσφαιρίνης 7g/dl με μέγιστο όριο τιμή αιμοσφαιρίνης 10g/dl. Μια ελεγμένη στρατηγική μετάγγισης είναι αποτελεσματικότερη και πιθανώς καλύτερη από μια ανεξέλεγτη μέθοδο, ιδιαίτερως σε ασθενείς βαρέως πάσχοντες (4). Λαμβάνοντας υπόψη την ασφάλεια, το κόστος και την έλλειψη μονάδων αίματος, οποιαδήποτε μετάγγιση σε ορθοπεδικά χειρουργεία πρέπει να εκτελείται με ιδιαίτερη προσοχή. Σε επεμβάσεις καταγμάτων ισχίου, η διεγχειρητική απώλεια άιματος και η μειωμένη ερυθροποίηση, που κατά κύριο λόγο οφείλεται στην επαγώμενη από το τραύμα φλεγμονή οδηγεί στο 90% των ασθενών σε μετεγχειρητική αναιμία (5). Η αναιμία σε ασθενείς με κατάγματα ισχίου, οι οποίοι συνήθως ανήκουν στην τρίτη ηλικία, μπορεί να προυπάρχει λόγω άλλων νοσημάτων, γεγονός που καθιστά ακόμα πιο αναγκαία την αντιμετώπιση της. Η αναιμία προκαλεί αιμοδυναμικό στρες, αυξημένες ανάγκες του μυοκαρδίου σε οξυγόνο και ιστική υποξία ιδιαίτερα σε ηλικιωμένους ασθενείς με κατάγματα ισχίου. Ιδιαιτέρως, σε ασθενείς με προυπάρχουσα καρδιακή νόσο, ο κίνδυνος είναι αυξημένος. Η πιθανότητα αύξησης των επιπέδων τροπονίνης μετά από ορθοπεδική επέμβαση είναι 22-52,9%. Συμπεραίνουμε, λοιπόν, ότι η αναιμία συνδέεται με αυξημένη νοσηρότητα και θνητότητα μετά από επεμβάσεις ισχίου. Επιπλέον, η αναιμία αποτελεί έναν ανεξάρτητο παράγοντα δυσκολίας κινητοποίησης των ασθενών μετεγχειρητικά. Η μετάγγιση αλλογενούς αίματος είναι η πιο κοινή τεχνική που χρησιμοποιείται για την οξεία και μετεγχειρητική αναιμία, ιδιαίτερα σε ασθενείς με χαμηλά επίπεδα αιμοσφαιρίνης προεγχειρητικά ή σε μη ειδικά χειρουργεία, καθώς μπορεί να αυξήσει πολύ γρήγορα τα επίπεδα της αιμοσφαιρίνης (6). Όμως, αποτελώντας ένα βιολογικό παράγοντα, η μετάγγιση ερυθρών ενέχει κινδύνους, όπως μετεγχειρητικές λοιμώξεις, συμπεριλαμβανόμενης της πνευμονίας, μετεγχειρητικό παραλήρημα και αύξηση του χρόνου παραμονής στο νοσοκομείο. Λαμβάνοντας όλα αυτά υπόψη, μια νέα μέθοδος ερευνάται με σκοπό να μειώσει την απώλεια αίματος και να μειώσει τις μεταγγίσεις και αυτή είναι η χορήγηση τρανεξαμικού οξέος.","abstract_html":"Τα κατάγματα ισχίου είναι από τις ορθοπεδικές επεμβάσεις που συνοδεύονται με τη μεγαλύτερη διεγχειρητική και μετεγχειρητική απώλεια αίματος (1). Η μετάγγιση συμπυκνωμένων ερυθρών αιμοσφαιρίων είναι ο συνήθης τρόπος αντιμετώπισης της απώλειας αίματος κατά τη διάρκεια των επεμβάσεων αυτών. Απώλεια αίματος της τάξης των 1000 ml συνήθως οδηγεί σε μετεγχειρητική αναιμία και απαιτεί μετάγγιση, μια πράξη που ελοχεύει τον κίνδυνο μετάδοσης ιογενών νοσημάτων, αλλεργικές και ανοσοτροποποιητικές αντιδράσεις (2). Συχνά υπάρχει το πρόβλημα των διαθέσιμων φιαλών αίματος οδηγώντας την ιατρική κοινότητα να ερευνήσει τρόπους ή παρεμβάσεις, που έχουν ως στόχο τη μείωση της ανάγκης των μεταγγίσεων (2). Η Μετάγγιση αίματος μετά από ορθοπεδικές επεμβάσεις ανήκει στο 10% όλων των μονάδων αίματος που χορηγούνται από την αιμοδοσία του Εθνικού Συστήματος Υγείας (3). Ο στόχος της μετάγγισης των ερυθρών αιμοσφαιρίων είναι να αυξήσει τη συγκέντρωση της αιμοσφαιρίνης και ως εκ τούτου τη μεταφορά του οξυγόνου στους ιστούς. Παρόλα ταύτα, δεν υπάρχουν κατευθυντήριες οδηγίες όσον αφορά στην μετάγγιση. Επιπρόσθετα, τα δεδομένα της τελευταίας δεκαετίας προτείνουν ως ασφαλές όριο μετάγγισης, τιμή αιμοσφαιρίνης 7g/dl με μέγιστο όριο τιμή αιμοσφαιρίνης 10g/dl. Μια ελεγμένη στρατηγική μετάγγισης είναι αποτελεσματικότερη και πιθανώς καλύτερη από μια ανεξέλεγτη μέθοδο, ιδιαίτερως σε ασθενείς βαρέως πάσχοντες (4). Λαμβάνοντας υπόψη την ασφάλεια, το κόστος και την έλλειψη μονάδων αίματος, οποιαδήποτε μετάγγιση σε ορθοπεδικά χειρουργεία πρέπει να εκτελείται με ιδιαίτερη προσοχή. Σε επεμβάσεις καταγμάτων ισχίου, η διεγχειρητική απώλεια άιματος και η μειωμένη ερυθροποίηση, που κατά κύριο λόγο οφείλεται στην επαγώμενη από το τραύμα φλεγμονή οδηγεί στο 90% των ασθενών σε μετεγχειρητική αναιμία (5). Η αναιμία σε ασθενείς με κατάγματα ισχίου, οι οποίοι συνήθως ανήκουν στην τρίτη ηλικία, μπορεί να προυπάρχει λόγω άλλων νοσημάτων, γεγονός που καθιστά ακόμα πιο αναγκαία την αντιμετώπιση της. Η αναιμία προκαλεί αιμοδυναμικό στρες, αυξημένες ανάγκες του μυοκαρδίου σε οξυγόνο και ιστική υποξία ιδιαίτερα σε ηλικιωμένους ασθενείς με κατάγματα ισχίου. Ιδιαιτέρως, σε ασθενείς με προυπάρχουσα καρδιακή νόσο, ο κίνδυνος είναι αυξημένος. Η πιθανότητα αύξησης των επιπέδων τροπονίνης μετά από ορθοπεδική επέμβαση είναι 22-52,9%. Συμπεραίνουμε, λοιπόν, ότι η αναιμία συνδέεται με αυξημένη νοσηρότητα και θνητότητα μετά από επεμβάσεις ισχίου. Επιπλέον, η αναιμία αποτελεί έναν ανεξάρτητο παράγοντα δυσκολίας κινητοποίησης των ασθενών μετεγχειρητικά. Η μετάγγιση αλλογενούς αίματος είναι η πιο κοινή τεχνική που χρησιμοποιείται για την οξεία και μετεγχειρητική αναιμία, ιδιαίτερα σε ασθενείς με χαμηλά επίπεδα αιμοσφαιρίνης προεγχειρητικά ή σε μη ειδικά χειρουργεία, καθώς μπορεί να αυξήσει πολύ γρήγορα τα επίπεδα της αιμοσφαιρίνης (6). Όμως, αποτελώντας ένα βιολογικό παράγοντα, η μετάγγιση ερυθρών ενέχει κινδύνους, όπως μετεγχειρητικές λοιμώξεις, συμπεριλαμβανόμενης της πνευμονίας, μετεγχειρητικό παραλήρημα και αύξηση του χρόνου παραμονής στο νοσοκομείο. Λαμβάνοντας όλα αυτά υπόψη, μια νέα μέθοδος ερευνάται με σκοπό να μειώσει την απώλεια αίματος και να μειώσει τις μεταγγίσεις και αυτή είναι η χορήγηση τρανεξαμικού οξέος.","abstract_has_math":false,"creators":["Τράντζας Παναγιώτης","Trantzas Panagiotis"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019","date_published":"2019","updated_at":"2026-11-19T05:35:29Z","subjects":["Επιστήμες Υγείας","Health Sciences"],"languages":["Ελληνικά","Greek"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:2876520"],"render_values":[{"text":"uoadl:2876520","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/2876520","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://pergamos.lib.uoa.gr/uoa/dl/object/2876520","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://pergamos.lib.uoa.gr/uoa/dl/frontend/oaipmh?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Alib.uoa.gr%3Auoadl%3A2876520","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Τράντζας Παναγιώτης","Trantzas Panagiotis"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019"]},{"key":"dc:type","label":"Dc Type","values":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Επιστήμες Υγείας","Health Sciences"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["Ελληνικά","Greek"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["uoadl:2876520","https://pergamos.lib.uoa.gr/uoa/dl/object/2876520"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Τα κατάγματα ισχίου είναι από τις ορθοπεδικές επεμβάσεις που συνοδεύονται με τη μεγαλύτερη διεγχειρητική και μετεγχειρητική απώλεια αίματος (1). Η μετάγγιση συμπυκνωμένων ερυθρών αιμοσφαιρίων είναι ο συνήθης τρόπος αντιμετώπισης της απώλειας αίματος κατά τη διάρκεια των επεμβάσεων αυτών. Απώλεια αίματος της τάξης των 1000 ml συνήθως οδηγεί σε μετεγχειρητική αναιμία και απαιτεί μετάγγιση, μια πράξη που ελοχεύει τον κίνδυνο μετάδοσης ιογενών νοσημάτων, αλλεργικές και ανοσοτροποποιητικές αντιδράσεις (2). Συχνά υπάρχει το πρόβλημα των διαθέσιμων φιαλών αίματος οδηγώντας την ιατρική κοινότητα να ερευνήσει τρόπους ή παρεμβάσεις, που έχουν ως στόχο τη μείωση της ανάγκης των μεταγγίσεων (2). Η Μετάγγιση αίματος μετά από ορθοπεδικές επεμβάσεις ανήκει στο 10% όλων των μονάδων αίματος που χορηγούνται από την αιμοδοσία του Εθνικού Συστήματος Υγείας (3). Ο στόχος της μετάγγισης των ερυθρών αιμοσφαιρίων είναι να αυξήσει τη συγκέντρωση της αιμοσφαιρίνης και ως εκ τούτου τη μεταφορά του οξυγόνου στους ιστούς. Παρόλα ταύτα, δεν υπάρχουν κατευθυντήριες οδηγίες όσον αφορά στην μετάγγιση. Επιπρόσθετα, τα δεδομένα της τελευταίας δεκαετίας προτείνουν ως ασφαλές όριο μετάγγισης, τιμή αιμοσφαιρίνης 7g/dl με μέγιστο όριο τιμή αιμοσφαιρίνης 10g/dl. Μια ελεγμένη στρατηγική μετάγγισης είναι αποτελεσματικότερη και πιθανώς καλύτερη από μια ανεξέλεγτη μέθοδο, ιδιαίτερως σε ασθενείς βαρέως πάσχοντες (4). Λαμβάνοντας υπόψη την ασφάλεια, το κόστος και την έλλειψη μονάδων αίματος, οποιαδήποτε μετάγγιση σε ορθοπεδικά χειρουργεία πρέπει να εκτελείται με ιδιαίτερη προσοχή. Σε επεμβάσεις καταγμάτων ισχίου, η διεγχειρητική απώλεια άιματος και η μειωμένη ερυθροποίηση, που κατά κύριο λόγο οφείλεται στην επαγώμενη από το τραύμα φλεγμονή οδηγεί στο 90% των ασθενών σε μετεγχειρητική αναιμία (5). Η αναιμία σε ασθενείς με κατάγματα ισχίου, οι οποίοι συνήθως ανήκουν στην τρίτη ηλικία, μπορεί να προυπάρχει λόγω άλλων νοσημάτων, γεγονός που καθιστά ακόμα πιο αναγκαία την αντιμετώπιση της. Η αναιμία προκαλεί αιμοδυναμικό στρες, αυξημένες ανάγκες του μυοκαρδίου σε οξυγόνο και ιστική υποξία ιδιαίτερα σε ηλικιωμένους ασθενείς με κατάγματα ισχίου. Ιδιαιτέρως, σε ασθενείς με προυπάρχουσα καρδιακή νόσο, ο κίνδυνος είναι αυξημένος. Η πιθανότητα αύξησης των επιπέδων τροπονίνης μετά από ορθοπεδική επέμβαση είναι 22-52,9%. Συμπεραίνουμε, λοιπόν, ότι η αναιμία συνδέεται με αυξημένη νοσηρότητα και θνητότητα μετά από επεμβάσεις ισχίου. Επιπλέον, η αναιμία αποτελεί έναν ανεξάρτητο παράγοντα δυσκολίας κινητοποίησης των ασθενών μετεγχειρητικά. Η μετάγγιση αλλογενούς αίματος είναι η πιο κοινή τεχνική που χρησιμοποιείται για την οξεία και μετεγχειρητική αναιμία, ιδιαίτερα σε ασθενείς με χαμηλά επίπεδα αιμοσφαιρίνης προεγχειρητικά ή σε μη ειδικά χειρουργεία, καθώς μπορεί να αυξήσει πολύ γρήγορα τα επίπεδα της αιμοσφαιρίνης (6). Όμως, αποτελώντας ένα βιολογικό παράγοντα, η μετάγγιση ερυθρών ενέχει κινδύνους, όπως μετεγχειρητικές λοιμώξεις, συμπεριλαμβανόμενης της πνευμονίας, μετεγχειρητικό παραλήρημα και αύξηση του χρόνου παραμονής στο νοσοκομείο. Λαμβάνοντας όλα αυτά υπόψη, μια νέα μέθοδος ερευνάται με σκοπό να μειώσει την απώλεια αίματος και να μειώσει τις μεταγγίσεις και αυτή είναι η χορήγηση τρανεξαμικού οξέος.","Introduction Hip fracture surgery is one of the bloodiest surgeries. Blood transfusion is usually the chosen way to replenish blood loss during surgery (1). A blood loss of 1000 ml usually results in postoperative anemia and requires a blood transfusion, a practice that encloses the possibility of transmission of blood infections resulting in allergic and immunomodulatory reactions (2). There is often a problem with availability in blood banks, making the scientific community seek new methods of intervention that will reduce the need for blood transfusion (2). Blood transfusion after orthopedic surgery may account for 10% of all red blood cell units delivered by the transfusion service at national health system (3). The normal goal of red blood cells (RBC) is to increase the ability to deliver more oxygen to the tissues by increasing the hemoglobin (Hb) concentration. However, there is no consensus on precise clinical indications of RBC administration, which leads to significant differences in their use. In addition, data from the last decade strongly suggests that a 7g/dl transfusion limit is safe and possibly up to a maximum of 10g/dl. A restrictive blood transfusion strategy is at least as effective and possibly better than a free-flowing regimen in critically ill patients (4). Taking into account the safety, cost and lack of blood availability, any transfusion into orthopedic surgery should be carefully considered. In hip surgery procedures, perioperative blood loss and post-operative erythropoiesis due to surgically induced inflammation may result in post-operative anemia in approximately 90% of patients (5). Allogeneic blood transfusion is the most commonly used measure for the treatment of acute and postoperative anemia, especially in patients with low pre-operative Hb levels or in non-selective surgery as it can rapidly increase Hb levels in patients (6). However, as a biological product, allogeneic blood supply will always involve risks. Taking these into consideration, a new method is employed to limit blood loss and thus allogeneic blood transfusions, the administration of tranexamic acid (TXA). Tranexamic acid TXA is an anti-fibrinolytic synthetic agent that binds plasminogen lysine receptors, acting as a competitive inhibitor of plasminogen (7). Current data suggest that TXA is an easily accessible and cost-effective treatment that can reduce blood loss during surgery and transfusion rates in a range of surgical experiments without increased risk of thrombosis (7, 8). The dosage of TXA is usually 10 mg / kg and according to the literature it appears to have positive results in blood loss in dental, gynecological, cardiac, orthopedic and other surgeries. This drug is successfully used in hemorrhages from traumatic or pathological causes (9). The benefit of TXA by intravenous or topical injection is not only the postoperative progression of the patient but also the cost of intervention, as TXA administration is much cheaper in comparison to blood transfusion. Blood loss in hip fracture surgery Despite current healthcare developments, hip fractures remain a significant risk group for mortality in the hospital, up to 5% (10). These deaths usually occur early in the postoperative period, with an average of 11 days after their introduction (11). Blood loss during surgery is an important, common and underestimated complication of hip fracture surgery associated with postoperative mortality (12, 13). In addition, postoperative anemia has been associated with increased impairment in functional capacity, longer duration of hospitalization and increased mortality (14). Typical treatment of postoperative anemia is through blood transfusion, with major orthopedic surgery being recognized as the most common indication of blood transfusion in patients after surgery (15). There is concern, however, about a significantly increased risk of severe bacterial infection in patients with hip fractures undergoing allogeneic blood transfusion (16). Use of TXA in hip fracture surgery Literature data about TXA usage in hip fracture surgery are scarce. Patients sustaining hip fractures are older, have lower preoperative Hb, and suffer from fragility and co-existing comorbidities; thus they are more susceptible to thromboembolic events in comparison with patients undergoing total hip or knee replacement (13). Scientific evidence suggests that TXA is useful for limiting blood loss and transfusion rate in hip fracture surgery. Studies on local TXA injection in the hip fracture have so far provided various estimates of its effectiveness in reducing blood loss and thromboembolic risk without clear signs of consensus (17). Overall, the potential benefits of the use of TXA in significantly reducing blood loss and transfusion rates are overwhelming. Moreover, TXA may improve functional recovery, diminish patient hospitalization and reduce total cost. In relation to the efficacy of intravenous use of TXA, most studies favor its administration in hip fracture surgery. Even though, there are few studies which have found no significant difference in total blood loss or blood transfusion rate, most studies have correlated TXA administration with less perioperative blood loss and reduced transfusion rates. The most recent meta-analyses were published in 2018 and 2019, by Zhang et al and Xiao et al, respectively, containing 11 studies concerning intravenous application of TXA and 3 studies about its topical use, on femoral fracture surgery. The results of the study showed that intravenous use of TXA was associated with less total blood loss, lower postoperative Hb decrease and lower transfusion rate, in comparison to placebo. No significant differences were identified concerning thromboembolic events, 90-day mortality and duration of surgery. Regarding topical use of TXA, no significant differences were found in the transfusion rate, postoperative Hb decrease, thromboembolic events and duration of surgery. Authors concluded that both intravenous and topical application of TXA decreased blood transfusion rate in hip surgery. However, more studies of higher quality are needed to elucidate the optimal route of administration, TXA dosage and timing (18, 19). Another recent meta-analysis analyzed a variety of studies with regard to the use of TXA in hip fracture surgery and resulted in the following: There was a 46% lower risk of requiring blood transfusion in those who received intravenous TXA compared to the control group or placebo. Post-operative hemoglobin was greater in intravenous TXA interventions than in the control or placebo group. Postoperative total blood loss was lower in those who received TXA intravenously compared to control or placebo. The meta-analysis showed significantly lower blood loss for TXA versus the control group. Total duration of hospitalization was not different between the 2 groups. Regarding the post-operative complications meta-analysis showed the following complications: 30th day mortality, 90th day mortality, heart attack, thromboembolic events, pulmonary embolism and severe venous thrombosis (20), A randomized, placebo-controlled study evaluating the efficacy of TXA in reducing blood loss in hip fracture patients comes in agreement with previous studies, but also raises doubts for the successful use of TXA. The authors have concluded that there is clinical uncertainty and lack of high quality data on the administration of TXA to patients with hip fracture (21). Despite the proven efficacy of its use in elective orthopedic surgery, optimal dosing and timing of TXA administration is still under discussion (22). In addition, the efficacy and side effects of TXA in patients with hip fractures remain unclear. Another randomized, double-blinded study compared 57 patients who received TXA intravenously with 53 patients who received placebo. All patients received surgical treatment for an isolated hip fracture. In TXA group, the transfusion rate was 42%, in comparison to the 60% of placebo group. However, authors stated that TXA may promote a hypercoagulable state (23). A similar randomized, double-blinded study, concerning hip fracture surgery, compared 45 patients who received TXA intravenously (500 mg preoperatively, followed by continuous infusion) with 45 patients who received placebo. Postoperative blood loss, measured by blood quantity in the drain, was significantly lower in TXA group, along with the mean postoperative Hb decrease and the blood transfusion requirements (24). Similar were the results of a study by Emara et al, who observed that topical use of TXA deceased postoperative blood loss; however authors were cautious about possible side-effects (17). Recently, another randomized, control trial, involving intramedullary nailing of intertrochanteric fractures, compared 50 patients who received TXA intravenously (2 doses of 10mg/kg body weight of TXA preoperatively and 3 hours postoperatively) with 50 patients who received normal saline. Mean postoperative Hb was significantly higher in TXA group. The rate of transfusion was 18% in TXA group, in comparison with 42% of control group (25). A single-centre placebo-controlled double-blinded randomized clinical trial, involving surgical treatment of extra-capsular hip fractures, compared 33 patients who received TXA with 39 controls. Authors noted a significant mean reduction of total blood loss in the TXA group along with a significant increase in 90-day mortality, focusing on the need of further safety investigation (26). Concerning intramedullary nailing of proximal femoral shaft fractures, Haghighi et al, conducted a double blind randomized controlled clinical trial, comparing the efficacy of 15 mg/kg intravenous infusion of TXA preoperatively, with normal saline in 38 patients. Authors concluded that Hb decline was lower in TXA group, without any significant difference in blood loss (27). Baruah et al compared periperative blood loss in 60 patients suffering from trochanteric fractures and treated with open reduction and internal fixation with a dynamic hip screw. After equal randomization, patients received either TXA intravenously (15 mg/kg) before surgery, or an equal volume of normal saline. Authors concluded that blood loss was lower in TXA group, along with the rate of transfusion (28). These results were confirmed by a randomized controlled study, conducted by Lei et al. Among 77 patients with intertrochanteric fracture, treated with intramedullary nailing, TXA significantly decreased postoperative blood loss (29). Similar were the results of a study by Watts et al, which assessed the administration of TXA during hemiarthroplasties for femoral neck fractures. TXA seemed to reduce blood loss along with the transfusion rate, without causing any difference in the frequency of adverse events (30). Optimal dosage of TXA in hip fracture surgery Nowadays, the most common way of intravenous TXA administration are preoperative dose of 1 – 2 gr or 10–15 mg/kg or combined preoperative and postoperative use. A recent study proved that preoperative administration of 1gr TXA may maintain plasma concentration of TXA for more than 10 mg/lt intraoperatively, for at least 3 hours, in hip arthroplasty. However, keeping TXA concentrations above 10 mg/lt for 16 hours could not further decrease blood loss (31). A study by Zufferey et al mentioned that a continuous infusion of 1 gr TXA after a preoperative bolus of TXA in hip arthroplasty did not further reduce blood loss (23). In 2018, Piolanti et al concluded that a regimen of 10 or 20 mg/kg produces similar results in total blood loss, advising that the use of two 10 mg/kg doses may not decrease the potential thromboembolic complications (32). In a recent study by Sun et al, authors concluded that one preoperative dosage and an additional intraoperative dosage of TXA were more effective in reducing blood loss in comparison with a single preoperative dosage of TXA (33). Optimal route of administration of TXA in hip fracture surgery Topical use of TXA has the major advantage of absence of systemic absorption. It has been reported that intraoperative topical administration of TXA around the fracture site in intertrochanteric fractures is safe and cost-effective, resulting in a significant decrease in perioperative blood loss and rate of transfusion (34). The study by Emara et al, showed that topical use of TXA, is safer than intravenous administration of TXA, decreasing blood loss and transfusion rate (17). On the contrary, another recent study concluded that TXA may not reduce postoperative blood loss when administered topically in peritrochanteric fracture surgery (35). The meta-analysis by Zhang et al, has concluded that topical administration of TXA is correlated with a lower transfusion rate (18). Potential side effects of TXA in hip fracture surgery Patients undergoing elective total arthroplasty and spinal surgery represent a different population compared to patients with hip fracture. A large proportion of patients with hip fracture have significant medical co-morbidities and many have a history of heart disease (36). While TXA has demonstrated its safety and efficacy in patients without significant cardiac disease undergoing elective surgery, there is still discussion whether TXA will have the same effect in patients with significant comorbidities (37). Data investigating TXA in patients with co-morbidity is limited, preventing several clinicians from using TXA in patients with hip fractures. However, the potential benefit of lowering blood loss and reducing the number of transfusions after hip fracture surgery is important and may lead to improved results with shorter patient hospitalizations and lower costs. It is believed that the potential benefit of administering TXA to such patients outweighs the risk of complications from using TXA. The majority of literature on the use of TXA has confirmed its safety and has limited concerns that its use will lead to higher rates of thrombosis (37-39). A recent meta-analysis assessed the efficacy of topical TXA in total hip arthroplasty, with a specific relation to the effective action of local infusion of TXA. Based on 14 studies of hip fracture patients, the most important findings of this meta-analysis were that, compared to the control group, local TXA infusion significantly reduced blood loss, transfusion rates, and showed a lower decrease in Hb levels. Another important finding of the meta-analysis was that topical administration of TXA did not appear to increase the risk of venous thrombosis and pulmonary embolism compared to the control group (40). A major research by Emara et al. included both intravenous and topical TXA infusion compared to conventional surgery. Authors used thromboelastogram for the monitoring of coagulation. The results of this study showed a significant reduction in blood loss both in the intravenous administration group and in the TXA topical injection group compared to the control group during the first 24 hours postoperatively (17). Most importantly, however, they have examined and confirmed the security of local TXA infusion. They observed that there was a 30% increase in the risk of thromboembolic events in the intravenous TXA administration group compared to the TXA topical injection group where the risk was zero and in the control group where it was 5% (17). A randomized, double-blinded study in 100 patients with hip fracture, mentioned that intravenous use of TXA enclosed a 3-fold increased risk (16%) in vascular events at 6 weeks postoperatively (23). However, most studies investigating the use of TXA in hip fracture surgery have proved its safety (28, 30, 41, 42). As TXA blocks the lysine-binding sites on plasminogen, de-activating plasminogen and hampering fibrinolysis, it does not increase fibrin production. Therefore, theoretically, TXA does not provoke a high coagulation state postoperatively, thus not increasing the possibility of deep venous thrombosis. An older study had suggested that administration of TXA does not influence the risk of thromboembolic events, as it blocks fibrinolysis only in the wound, and not systematically (43). A large multi-center study in more than 20.000 patients suffering from significant hemorrhage showed that TXA administration safely decreased the possibility of death in bleeding trauma patients (44). Another retrospective, multi-center study, in more than 870.000 patients undergoing total joint arthroplasty showed that TXA administration was not correlated with a higher risk of complications, including deep venous thrombosis, pulmonary embolism and renal failure (41). Conclusions TXA, having the potential to reduce transfusion rates by limiting blood loss, may reduce hospital stay and improve results in hundreds of thousands of hip fracture patients per year. Further research on TXA actions is needed. Specifically, large randomized, double-blinded studies are needed, with larger follow-up, investigating different dosages and routes of TXA administration and focusing on TXA safety on the elderly population. If the new innovative studies on the efficacy of TXA in hip fracture patients demonstrate their ability to cope with the complications of the intervention, they will be able to change the level of care for many of these patients and save a reasonable amount of resources for the National Health System."]},{"key":"dc:title","label":"Title","values":["Χρήση τρανεξαμικού οξέoς στη χειρουργική αντιμετώπιση των καταγμάτων ισχίου- ανασκόπηση"]}]}],"canonical_facts":{"dc:creator":["Τράντζας Παναγιώτης","Trantzas Panagiotis"],"dc:date":["2019"],"dc:description":["Τα κατάγματα ισχίου είναι από τις ορθοπεδικές επεμβάσεις που συνοδεύονται με τη μεγαλύτερη διεγχειρητική και μετεγχειρητική απώλεια αίματος (1). Η μετάγγιση συμπυκνωμένων ερυθρών αιμοσφαιρίων είναι ο συνήθης τρόπος αντιμετώπισης της απώλειας αίματος κατά τη διάρκεια των επεμβάσεων αυτών. Απώλεια αίματος της τάξης των 1000 ml συνήθως οδηγεί σε μετεγχειρητική αναιμία και απαιτεί μετάγγιση, μια πράξη που ελοχεύει τον κίνδυνο μετάδοσης ιογενών νοσημάτων, αλλεργικές και ανοσοτροποποιητικές αντιδράσεις (2). Συχνά υπάρχει το πρόβλημα των διαθέσιμων φιαλών αίματος οδηγώντας την ιατρική κοινότητα να ερευνήσει τρόπους ή παρεμβάσεις, που έχουν ως στόχο τη μείωση της ανάγκης των μεταγγίσεων (2). Η Μετάγγιση αίματος μετά από ορθοπεδικές επεμβάσεις ανήκει στο 10% όλων των μονάδων αίματος που χορηγούνται από την αιμοδοσία του Εθνικού Συστήματος Υγείας (3). Ο στόχος της μετάγγισης των ερυθρών αιμοσφαιρίων είναι να αυξήσει τη συγκέντρωση της αιμοσφαιρίνης και ως εκ τούτου τη μεταφορά του οξυγόνου στους ιστούς. Παρόλα ταύτα, δεν υπάρχουν κατευθυντήριες οδηγίες όσον αφορά στην μετάγγιση. Επιπρόσθετα, τα δεδομένα της τελευταίας δεκαετίας προτείνουν ως ασφαλές όριο μετάγγισης, τιμή αιμοσφαιρίνης 7g/dl με μέγιστο όριο τιμή αιμοσφαιρίνης 10g/dl. Μια ελεγμένη στρατηγική μετάγγισης είναι αποτελεσματικότερη και πιθανώς καλύτερη από μια ανεξέλεγτη μέθοδο, ιδιαίτερως σε ασθενείς βαρέως πάσχοντες (4). Λαμβάνοντας υπόψη την ασφάλεια, το κόστος και την έλλειψη μονάδων αίματος, οποιαδήποτε μετάγγιση σε ορθοπεδικά χειρουργεία πρέπει να εκτελείται με ιδιαίτερη προσοχή. Σε επεμβάσεις καταγμάτων ισχίου, η διεγχειρητική απώλεια άιματος και η μειωμένη ερυθροποίηση, που κατά κύριο λόγο οφείλεται στην επαγώμενη από το τραύμα φλεγμονή οδηγεί στο 90% των ασθενών σε μετεγχειρητική αναιμία (5). Η αναιμία σε ασθενείς με κατάγματα ισχίου, οι οποίοι συνήθως ανήκουν στην τρίτη ηλικία, μπορεί να προυπάρχει λόγω άλλων νοσημάτων, γεγονός που καθιστά ακόμα πιο αναγκαία την αντιμετώπιση της. Η αναιμία προκαλεί αιμοδυναμικό στρες, αυξημένες ανάγκες του μυοκαρδίου σε οξυγόνο και ιστική υποξία ιδιαίτερα σε ηλικιωμένους ασθενείς με κατάγματα ισχίου. Ιδιαιτέρως, σε ασθενείς με προυπάρχουσα καρδιακή νόσο, ο κίνδυνος είναι αυξημένος. Η πιθανότητα αύξησης των επιπέδων τροπονίνης μετά από ορθοπεδική επέμβαση είναι 22-52,9%. Συμπεραίνουμε, λοιπόν, ότι η αναιμία συνδέεται με αυξημένη νοσηρότητα και θνητότητα μετά από επεμβάσεις ισχίου. Επιπλέον, η αναιμία αποτελεί έναν ανεξάρτητο παράγοντα δυσκολίας κινητοποίησης των ασθενών μετεγχειρητικά. Η μετάγγιση αλλογενούς αίματος είναι η πιο κοινή τεχνική που χρησιμοποιείται για την οξεία και μετεγχειρητική αναιμία, ιδιαίτερα σε ασθενείς με χαμηλά επίπεδα αιμοσφαιρίνης προεγχειρητικά ή σε μη ειδικά χειρουργεία, καθώς μπορεί να αυξήσει πολύ γρήγορα τα επίπεδα της αιμοσφαιρίνης (6). Όμως, αποτελώντας ένα βιολογικό παράγοντα, η μετάγγιση ερυθρών ενέχει κινδύνους, όπως μετεγχειρητικές λοιμώξεις, συμπεριλαμβανόμενης της πνευμονίας, μετεγχειρητικό παραλήρημα και αύξηση του χρόνου παραμονής στο νοσοκομείο. Λαμβάνοντας όλα αυτά υπόψη, μια νέα μέθοδος ερευνάται με σκοπό να μειώσει την απώλεια αίματος και να μειώσει τις μεταγγίσεις και αυτή είναι η χορήγηση τρανεξαμικού οξέος.","Introduction Hip fracture surgery is one of the bloodiest surgeries. Blood transfusion is usually the chosen way to replenish blood loss during surgery (1). A blood loss of 1000 ml usually results in postoperative anemia and requires a blood transfusion, a practice that encloses the possibility of transmission of blood infections resulting in allergic and immunomodulatory reactions (2). There is often a problem with availability in blood banks, making the scientific community seek new methods of intervention that will reduce the need for blood transfusion (2). Blood transfusion after orthopedic surgery may account for 10% of all red blood cell units delivered by the transfusion service at national health system (3). The normal goal of red blood cells (RBC) is to increase the ability to deliver more oxygen to the tissues by increasing the hemoglobin (Hb) concentration. However, there is no consensus on precise clinical indications of RBC administration, which leads to significant differences in their use. In addition, data from the last decade strongly suggests that a 7g/dl transfusion limit is safe and possibly up to a maximum of 10g/dl. A restrictive blood transfusion strategy is at least as effective and possibly better than a free-flowing regimen in critically ill patients (4). Taking into account the safety, cost and lack of blood availability, any transfusion into orthopedic surgery should be carefully considered. In hip surgery procedures, perioperative blood loss and post-operative erythropoiesis due to surgically induced inflammation may result in post-operative anemia in approximately 90% of patients (5). Allogeneic blood transfusion is the most commonly used measure for the treatment of acute and postoperative anemia, especially in patients with low pre-operative Hb levels or in non-selective surgery as it can rapidly increase Hb levels in patients (6). However, as a biological product, allogeneic blood supply will always involve risks. Taking these into consideration, a new method is employed to limit blood loss and thus allogeneic blood transfusions, the administration of tranexamic acid (TXA). Tranexamic acid TXA is an anti-fibrinolytic synthetic agent that binds plasminogen lysine receptors, acting as a competitive inhibitor of plasminogen (7). Current data suggest that TXA is an easily accessible and cost-effective treatment that can reduce blood loss during surgery and transfusion rates in a range of surgical experiments without increased risk of thrombosis (7, 8). The dosage of TXA is usually 10 mg / kg and according to the literature it appears to have positive results in blood loss in dental, gynecological, cardiac, orthopedic and other surgeries. This drug is successfully used in hemorrhages from traumatic or pathological causes (9). The benefit of TXA by intravenous or topical injection is not only the postoperative progression of the patient but also the cost of intervention, as TXA administration is much cheaper in comparison to blood transfusion. Blood loss in hip fracture surgery Despite current healthcare developments, hip fractures remain a significant risk group for mortality in the hospital, up to 5% (10). These deaths usually occur early in the postoperative period, with an average of 11 days after their introduction (11). Blood loss during surgery is an important, common and underestimated complication of hip fracture surgery associated with postoperative mortality (12, 13). In addition, postoperative anemia has been associated with increased impairment in functional capacity, longer duration of hospitalization and increased mortality (14). Typical treatment of postoperative anemia is through blood transfusion, with major orthopedic surgery being recognized as the most common indication of blood transfusion in patients after surgery (15). There is concern, however, about a significantly increased risk of severe bacterial infection in patients with hip fractures undergoing allogeneic blood transfusion (16). Use of TXA in hip fracture surgery Literature data about TXA usage in hip fracture surgery are scarce. Patients sustaining hip fractures are older, have lower preoperative Hb, and suffer from fragility and co-existing comorbidities; thus they are more susceptible to thromboembolic events in comparison with patients undergoing total hip or knee replacement (13). Scientific evidence suggests that TXA is useful for limiting blood loss and transfusion rate in hip fracture surgery. Studies on local TXA injection in the hip fracture have so far provided various estimates of its effectiveness in reducing blood loss and thromboembolic risk without clear signs of consensus (17). Overall, the potential benefits of the use of TXA in significantly reducing blood loss and transfusion rates are overwhelming. Moreover, TXA may improve functional recovery, diminish patient hospitalization and reduce total cost. In relation to the efficacy of intravenous use of TXA, most studies favor its administration in hip fracture surgery. Even though, there are few studies which have found no significant difference in total blood loss or blood transfusion rate, most studies have correlated TXA administration with less perioperative blood loss and reduced transfusion rates. The most recent meta-analyses were published in 2018 and 2019, by Zhang et al and Xiao et al, respectively, containing 11 studies concerning intravenous application of TXA and 3 studies about its topical use, on femoral fracture surgery. The results of the study showed that intravenous use of TXA was associated with less total blood loss, lower postoperative Hb decrease and lower transfusion rate, in comparison to placebo. No significant differences were identified concerning thromboembolic events, 90-day mortality and duration of surgery. Regarding topical use of TXA, no significant differences were found in the transfusion rate, postoperative Hb decrease, thromboembolic events and duration of surgery. Authors concluded that both intravenous and topical application of TXA decreased blood transfusion rate in hip surgery. However, more studies of higher quality are needed to elucidate the optimal route of administration, TXA dosage and timing (18, 19). Another recent meta-analysis analyzed a variety of studies with regard to the use of TXA in hip fracture surgery and resulted in the following: There was a 46% lower risk of requiring blood transfusion in those who received intravenous TXA compared to the control group or placebo. Post-operative hemoglobin was greater in intravenous TXA interventions than in the control or placebo group. Postoperative total blood loss was lower in those who received TXA intravenously compared to control or placebo. The meta-analysis showed significantly lower blood loss for TXA versus the control group. Total duration of hospitalization was not different between the 2 groups. Regarding the post-operative complications meta-analysis showed the following complications: 30th day mortality, 90th day mortality, heart attack, thromboembolic events, pulmonary embolism and severe venous thrombosis (20), A randomized, placebo-controlled study evaluating the efficacy of TXA in reducing blood loss in hip fracture patients comes in agreement with previous studies, but also raises doubts for the successful use of TXA. The authors have concluded that there is clinical uncertainty and lack of high quality data on the administration of TXA to patients with hip fracture (21). Despite the proven efficacy of its use in elective orthopedic surgery, optimal dosing and timing of TXA administration is still under discussion (22). In addition, the efficacy and side effects of TXA in patients with hip fractures remain unclear. Another randomized, double-blinded study compared 57 patients who received TXA intravenously with 53 patients who received placebo. All patients received surgical treatment for an isolated hip fracture. In TXA group, the transfusion rate was 42%, in comparison to the 60% of placebo group. However, authors stated that TXA may promote a hypercoagulable state (23). A similar randomized, double-blinded study, concerning hip fracture surgery, compared 45 patients who received TXA intravenously (500 mg preoperatively, followed by continuous infusion) with 45 patients who received placebo. Postoperative blood loss, measured by blood quantity in the drain, was significantly lower in TXA group, along with the mean postoperative Hb decrease and the blood transfusion requirements (24). Similar were the results of a study by Emara et al, who observed that topical use of TXA deceased postoperative blood loss; however authors were cautious about possible side-effects (17). Recently, another randomized, control trial, involving intramedullary nailing of intertrochanteric fractures, compared 50 patients who received TXA intravenously (2 doses of 10mg/kg body weight of TXA preoperatively and 3 hours postoperatively) with 50 patients who received normal saline. Mean postoperative Hb was significantly higher in TXA group. The rate of transfusion was 18% in TXA group, in comparison with 42% of control group (25). A single-centre placebo-controlled double-blinded randomized clinical trial, involving surgical treatment of extra-capsular hip fractures, compared 33 patients who received TXA with 39 controls. Authors noted a significant mean reduction of total blood loss in the TXA group along with a significant increase in 90-day mortality, focusing on the need of further safety investigation (26). Concerning intramedullary nailing of proximal femoral shaft fractures, Haghighi et al, conducted a double blind randomized controlled clinical trial, comparing the efficacy of 15 mg/kg intravenous infusion of TXA preoperatively, with normal saline in 38 patients. Authors concluded that Hb decline was lower in TXA group, without any significant difference in blood loss (27). Baruah et al compared periperative blood loss in 60 patients suffering from trochanteric fractures and treated with open reduction and internal fixation with a dynamic hip screw. After equal randomization, patients received either TXA intravenously (15 mg/kg) before surgery, or an equal volume of normal saline. Authors concluded that blood loss was lower in TXA group, along with the rate of transfusion (28). These results were confirmed by a randomized controlled study, conducted by Lei et al. Among 77 patients with intertrochanteric fracture, treated with intramedullary nailing, TXA significantly decreased postoperative blood loss (29). Similar were the results of a study by Watts et al, which assessed the administration of TXA during hemiarthroplasties for femoral neck fractures. TXA seemed to reduce blood loss along with the transfusion rate, without causing any difference in the frequency of adverse events (30). Optimal dosage of TXA in hip fracture surgery Nowadays, the most common way of intravenous TXA administration are preoperative dose of 1 – 2 gr or 10–15 mg/kg or combined preoperative and postoperative use. A recent study proved that preoperative administration of 1gr TXA may maintain plasma concentration of TXA for more than 10 mg/lt intraoperatively, for at least 3 hours, in hip arthroplasty. However, keeping TXA concentrations above 10 mg/lt for 16 hours could not further decrease blood loss (31). A study by Zufferey et al mentioned that a continuous infusion of 1 gr TXA after a preoperative bolus of TXA in hip arthroplasty did not further reduce blood loss (23). In 2018, Piolanti et al concluded that a regimen of 10 or 20 mg/kg produces similar results in total blood loss, advising that the use of two 10 mg/kg doses may not decrease the potential thromboembolic complications (32). In a recent study by Sun et al, authors concluded that one preoperative dosage and an additional intraoperative dosage of TXA were more effective in reducing blood loss in comparison with a single preoperative dosage of TXA (33). Optimal route of administration of TXA in hip fracture surgery Topical use of TXA has the major advantage of absence of systemic absorption. It has been reported that intraoperative topical administration of TXA around the fracture site in intertrochanteric fractures is safe and cost-effective, resulting in a significant decrease in perioperative blood loss and rate of transfusion (34). The study by Emara et al, showed that topical use of TXA, is safer than intravenous administration of TXA, decreasing blood loss and transfusion rate (17). On the contrary, another recent study concluded that TXA may not reduce postoperative blood loss when administered topically in peritrochanteric fracture surgery (35). The meta-analysis by Zhang et al, has concluded that topical administration of TXA is correlated with a lower transfusion rate (18). Potential side effects of TXA in hip fracture surgery Patients undergoing elective total arthroplasty and spinal surgery represent a different population compared to patients with hip fracture. A large proportion of patients with hip fracture have significant medical co-morbidities and many have a history of heart disease (36). While TXA has demonstrated its safety and efficacy in patients without significant cardiac disease undergoing elective surgery, there is still discussion whether TXA will have the same effect in patients with significant comorbidities (37). Data investigating TXA in patients with co-morbidity is limited, preventing several clinicians from using TXA in patients with hip fractures. However, the potential benefit of lowering blood loss and reducing the number of transfusions after hip fracture surgery is important and may lead to improved results with shorter patient hospitalizations and lower costs. It is believed that the potential benefit of administering TXA to such patients outweighs the risk of complications from using TXA. The majority of literature on the use of TXA has confirmed its safety and has limited concerns that its use will lead to higher rates of thrombosis (37-39). A recent meta-analysis assessed the efficacy of topical TXA in total hip arthroplasty, with a specific relation to the effective action of local infusion of TXA. Based on 14 studies of hip fracture patients, the most important findings of this meta-analysis were that, compared to the control group, local TXA infusion significantly reduced blood loss, transfusion rates, and showed a lower decrease in Hb levels. Another important finding of the meta-analysis was that topical administration of TXA did not appear to increase the risk of venous thrombosis and pulmonary embolism compared to the control group (40). A major research by Emara et al. included both intravenous and topical TXA infusion compared to conventional surgery. Authors used thromboelastogram for the monitoring of coagulation. The results of this study showed a significant reduction in blood loss both in the intravenous administration group and in the TXA topical injection group compared to the control group during the first 24 hours postoperatively (17). Most importantly, however, they have examined and confirmed the security of local TXA infusion. They observed that there was a 30% increase in the risk of thromboembolic events in the intravenous TXA administration group compared to the TXA topical injection group where the risk was zero and in the control group where it was 5% (17). A randomized, double-blinded study in 100 patients with hip fracture, mentioned that intravenous use of TXA enclosed a 3-fold increased risk (16%) in vascular events at 6 weeks postoperatively (23). However, most studies investigating the use of TXA in hip fracture surgery have proved its safety (28, 30, 41, 42). As TXA blocks the lysine-binding sites on plasminogen, de-activating plasminogen and hampering fibrinolysis, it does not increase fibrin production. Therefore, theoretically, TXA does not provoke a high coagulation state postoperatively, thus not increasing the possibility of deep venous thrombosis. An older study had suggested that administration of TXA does not influence the risk of thromboembolic events, as it blocks fibrinolysis only in the wound, and not systematically (43). A large multi-center study in more than 20.000 patients suffering from significant hemorrhage showed that TXA administration safely decreased the possibility of death in bleeding trauma patients (44). Another retrospective, multi-center study, in more than 870.000 patients undergoing total joint arthroplasty showed that TXA administration was not correlated with a higher risk of complications, including deep venous thrombosis, pulmonary embolism and renal failure (41). Conclusions TXA, having the potential to reduce transfusion rates by limiting blood loss, may reduce hospital stay and improve results in hundreds of thousands of hip fracture patients per year. Further research on TXA actions is needed. Specifically, large randomized, double-blinded studies are needed, with larger follow-up, investigating different dosages and routes of TXA administration and focusing on TXA safety on the elderly population. If the new innovative studies on the efficacy of TXA in hip fracture patients demonstrate their ability to cope with the complications of the intervention, they will be able to change the level of care for many of these patients and save a reasonable amount of resources for the National Health System."],"dc:identifier":["uoadl:2876520","https://pergamos.lib.uoa.gr/uoa/dl/object/2876520"],"dc:language":["Ελληνικά","Greek"],"dc:subject":["Επιστήμες Υγείας","Health Sciences"],"dc:title":["Χρήση τρανεξαμικού οξέoς στη χειρουργική αντιμετώπιση των καταγμάτων ισχίου- ανασκόπηση"],"dc:type":["born_digital_postgraduate_thesis","Διπλωματική Εργασία","Postgraduate Thesis"]},"updated_at":"2026-11-19T05:35:29Z"}